# Cellerant Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellerant-therapeutics

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.cellerant.com
- Total disclosed funding: $44M
- Latest round: Series B (Apr 21, 2011)
- Investors on record: 7

## About

Cellerant Therapeutics is focused on developing advanced cellular therapies for patients with hematologic malignancies and other diseases, utilizing innovative technology to enhance treatment efficacy.Founded in 2003 and headquartered in San Carlos, US, Cellerant Therapeutics specializes in cellular therapies. The firm has not indicated any pivots in business strategy. CEO Ram Mandalam leads the company, which has completed a total of 18 deals. The most recent funding round occurred on September 11, 2014, when Cellerant raised USD 47.5 mn in Grant funding from the Biomedical Advanced Research and Development Authority, contributing to a total amount raised of USD 2.09 mn.Cellerant Therapeutics provides innovative cellular therapies aimed at treating hematologic malignancies and various other healthcare challenges. Their core offerings include proprietary technology-driven platforms that improve treatment outcomes for patients. These therapies are tailored to address the needs of healthcare providers, ensuring effective patient management and care. Cellerant's products are primarily marketed in North America and Europe, targeting healthcare institutions striving for enhanced therapeutic solutions.Cellerant Therapeutics generates revenue through a structured model primarily based on partnerships with healthcare providers. Their financing model often involves grants and collaborations, ensuring continual support for their innovative therapies. This approach fosters long-term relationships with healthcare organizations while providing essential resources and therapy updates to their clients.Cellerant Therapeutics aims to expand its product line with new cellular therapies designed to address additional hematologic conditions by 2025. The company also plans to increase its market presence in Europe and Asia, targeting healthcare sectors in these regions for growth. The recent funding of USD 47.5 mn will be utilized to support the development of these upcoming therapies and facilitate their entry into new markets.

## Funding rounds

- Series B, Apr 21, 2011, $1M — Allen & Company, The Camelot Group, Sagamore Investments
- Series D, Oct 14, 2008, $3.1M — Allen & Company, The Camelot Group
- Series B, Apr 26, 2007, $4.4M — Allen & Company, Cheng Xin Venture Capital Group, The Camelot Group, MPM BioImpact, Novel Bioventures
- Series B, Sep 22, 2005, $9M — TaiAn Technologies Corporation, The Camelot Group
- Series B, May 11, 2005, $16M — Allen & Company, Cheng Xin Venture Capital Group, MPM BioImpact, Novel Bioventures
- Series A, May 29, 2003, $10M — Allen & Company, MPM BioImpact

## Investors

- Allen & Company — Series A, Series B, Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- Cheng Xin Venture Capital Group (https://capitalatlas.ai/funds/cheng-xin-venture-capital-group) — Series B
- Novel Bioventures — Series B
- TaiAn Technologies Corporation (https://capitalatlas.ai/funds/taian-technologies-corporation) — Series B
- The Camelot Group (https://capitalatlas.ai/funds/the-camelot-group) — Series B, Series D
- Sagamore Investments — Series B